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ABSTRACT
Project I:
Currently, chemotherapy is the only treatment for metastatic prostate cancer.
However, due to toxicity and resistance, the currently available chemotherapeutic
drugs are not good enough to control this disease. To find a novel and effective
method to treat this disease, we studied the effect of interferons (IFNs) and
double-stranded RNA (dsRNA) on the apoptosis of prostate cancer cells.
Interestingly, pretreatment of PC3 cells, a human prostate adenocarcinoma cell
line, with IFNs significantly sensitized these cells to dsRNA induced apoptosis,
and cell apoptosis was confirmed by a variety of assays such as Annexin V,
TUNEL, DNA fragmentation and the activity of caspase 3. In comparison with
IFN-α or  treatment, IFN-γ treatment remarkably augmented dsRNA-induced
apoptosis in PC3 cells. By using mutant cell lines, we demonstrated that IFNsignaling is necessary for these effects. Silence of dsRNA-dependent protein
kinase R (PKR) and RNAse L by siRNA did not have any significant impact on
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this event, suggesting that neither RNase L nor PKR is involved. Further
investigation of the apoptotic pathway revealed that Bak, a pro-apoptotic member
of the Bcl-2 family, is up-regulated by IFN-γ and dsRNA. Our findings may lead to
the design of novel therapeutic strategies for prostate cancer.

Project II:
Transmembrane and coiled-coil domains 1 (TMCO1) is a membraneassociated protein with unknown function. Recently, a homozygous frame shift
mutation, c.139_140delAG, has been identified in the TMCO1 gene in patients
with TMCO1 defect syndrome (TDS). TDS is characterized by distinctive
craniofacial dysmorphism, skeletal anomalies, and mental retardation. In order to
study the biological function of this gene, human TMCO1 was expressed in both
bacteria and mammalian cells. The recombinant TMCO1 expressed in bacteria
was purified in order to prepare an antibody, and subcellular localization revealed
that TMCO1 may be expressed in the mitochondria of cells. Further study
showed that the lymphocytes isolated from peripheral blood of patients with TDS
grew significantly faster than those from healthy individuals, suggesting that
TMCO1 may be involved in the regulation of cell proliferation. In addition, we
have generated a TMCO1 knock down cell line, which will be used to further
study the molecular basis of TDS.
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CHAPTER I
INTRODUCTION

Project I: Human prostate cancer cell apoptosis induced by interferon-γ
(IFN- γ) and double-stranded RNA (dsRNA)

1.1.1 Prostate cancer: epidemiology and treatment
The prostate is a small gland situated just below the bladder and surrounding
the urethra (Figure 1.1.1). Its size and shape are similar to a walnut [American
cancer society, 2009]. The function of a prostate is to produce the seminal fluid
through which sperm is transported. Usually prostate cancer arises if the prostate
cells fail to grow in an organized and controlled manner, which eventually leads
to the formation of a tumor.

1

Figure 1.1.1 Prostate cancer [American cancer society, 2009]
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In developed countries, prostate cancer is the second most frequently
diagnosed cancer in men. Although prostate specific antigen (PSA) screening
and early detection have been undertaken to reduce the mortality [Baade, et al.,
2004], prostate cancer is still the second leading cause of cancer death in men,
affecting about one in six men in the United States [Damber, et al., 2008]. The
American Cancer Society estimates that there were about 192,280 new cases of
prostate cancer in the United States in 2009 and that about 27,360 men died of
the disease during that year.
The treatment of prostate cancer depends on the cancerous stages of
patients. Localized disease is curable. For aged patients, especially with slowly
growing tumors, watchful waiting may be suggested. In the case of young
patients and fast growing tumors, the most common treatments are radical
prostatectomy and transurethral resection of the prostate [Chowdhury, et al.,
2007; Strief, et al., 2007]. Radiation therapy, a treatment with radiation to kill and
shrink cancer cells, is applied as the first treatment for low-grade cancer that has
not spread outside the prostate gland or to local tissues. Cryosurgery, a
technique using metal probes to freeze prostate cancer cells, can also be used
for the treatment of prostate cancer that has not spread. For men who are
diagnosed with a metastatic disease, there is only one choice: the androgenablation therapy, also called hormonal therapy. This treatment decreases the
level of androgen, causing the prostate tumor to shrink or to grow more slowly.
Unfortunately, hormonal therapy is effective for an average of only 2 years and
most patients eventually become refractory to hormonal therapy. Hormone-
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refractory prostate cancer (HRPC) is a common condition that causes
considerable morbidity and mortality.

To date, cytotoxic chemotherapy is

thought to be the best way to control this situation. Recent studies have shown
that docetaxel chemotherapy can achieve a remarkable improvement on the
survival of HRPC patients. Thus docetaxel treatment has become the first-line
chemotherapy treatment for HRPC and has been approved for use in the United
States and Europe. However, lack of a response and development of resistance
to docetaxel in a considerable number of patients limit its applications in prostate
cancer therapy, requiring that most patients with HRPC undergo as much as
third-line treatments [Chang and Kibel, 2008]. Therefore, development and
discovery of new drugs capable of prolonging survival have become an urgent
clinical need.

1.1.2 Overview of the IFN system and their biological functions
IFNs are a family of cytokines expressed in all eukaryotic cells as an early
response to multiple stimuli, such as viral infection, dsRNA, and immune
inducers [Stark, et al., 1998]. There are two major classes of IFNs: type I and
type II. Type I IFNs consist of several subtypes, mainly IFN-α and IFN-, and are
induced in most cell types by viruses and dsRNA; whereas type II IFN is induced
potentially in T lymphocytes and natural killer cells in response to immune and
inflammatory stimulation [Samuel, et al., 2001]. Most recently, a new type of IFNlike protein was identified and classified as Type III IFN or IFN-λ [Kotenko, et al.,
2003].
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Despite the differences in their amino acid sequences, all three types of IFNs
display similar biological responses through inducing the expression of a series
of IFN-stimulated genes (ISGs). The well-established IFN signaling pathways
involve tyrosine phosphorylation, the activation of the Janus tyrosine kinases
(JAKs), and the signal transducers and activators of transcription (STATs).
Although the JAK/STAT signaling pathway is used by all three types of IFNs, the
components and transducing mode in the pathways are distinctive (Figure 1.1.2).
After binding with type I IFN, dimerization of type I IFN receptor subunits,
IFNAR1 and IFNAR2, leads to the initiation of a tyrosine phosphorylation
cascade (JAK1 and Tyk2), resulting in the association of STAT1 and STAT2. The
phosphorylated STAT1/STAT2 heterodimer is associated with the DNA-binding
protein p48 (in cytoplasm) to form a heterotrimer complex (ISGF3) which
translocates into the nucleus, binding to the IFN-stimulated regulatory element
(ISRE) of type I IFN responsive genes to initiate transcription. In type II IFN
signaling, the activated type II receptor subunits IFNGR1 and IFNGR2 are
associated with and activate JAK1 and JAK2, which subsequently phosphorylate
STAT1. The phosphorylated STAT1 forms a homodimer, which translocates to
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Figure 1.1.2 IFN signaling pathway [Kotenko, et al., 2003]
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the nucleus where it binds to the gamma-activated sequence (GAS) of IFN-γinducible genes to stimulate transcription.

The type III IFN uses the same

JAK/STAT pathway as type I IFN, but through different receptors. In recent years,
studies have revealed that IFNs are able to activate other signaling pathways,
such as the mitogen activated protein kinase (MAPK) and phosphatidylinositol 3kinase (PI3-K) pathways [Platanias and Fish, 1999]. However, the biological
significance of this cross-talk between IFN signaling and other signaling
pathways remains to be fully understood.

1.1.3 IFNs and apoptosis
Apoptosis is a naturally occurring process by which a cell is directed to the
programmed death. Apoptosis serves to eliminate undesired or superfluous cells
in a targeted manner and plays an important role in tissue development,
homeostasis, and differentiation. When cells go through apoptotic characteristics,
changes take place in cell morphology, condensation of the chromatin,
degradation of DNA, and cell shrinkage. Other commonly used biomarkers
include cleavage of poly (ADP-ribose) polymerase (PARP), release of
cytochrome C from mitochondria, and an increase of caspase activities.
Additionally, apoptosis is involved in regulating the functions of the immune
system and eliminating altered cells. Thus, abnormalities in the regulation of cell
apoptosis can lead to various diseases, including cancer, autoimmunity, and
degenerative disorders [Pommier, et al., 2001; Schulze-Bergkamen and
Krammer, 2004; Liu et al., 2004; Tatton, et al., 2003; Roth, 2001].
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Type I and Type II IFNs are able to effectively induce apoptosis in a wide
range of malignant cell types, such as herpes-associated lymphomas, acute
promyelocytic leukemia (APL), non-small-cell lung cancer, non-melanoma skin
cancer and glioma [Barber, 2003]. It is believed that IFNs induce cell apoptosis
through activating the death receptor cascade (Figure 1.1.3) [Chawla-Sarkar, et
al., 2003]. The induction of TRAIL, and/or Fas/FasL, in response to IFNs leads to
recruitment and activation of FADD. FADD activation in turn activates caspase-8,
initiating the activation of the caspase cascade. On the other hand, IFNs also
induce caspase-4 and caspase-8. Activated caspase-8 cleaves Bid, a
proapoptotic member of Bcl-2 family, resulting in disruption of mitochondrial
potential and the release of cytochrome C from the mitochondria into the
cytoplasm where it acts as a cofactor to stimulate the complex of Apaf1 with
caspase-9, subsequently activating proscaspase-3. A variety of ISGs, including
the members of the IFN regulatory factor (IRF) family, dsRNA dependent protein
kinase (PKR), 2-5A dependent RNase L (RNase L), TNF-related apoptosisinducing ligand (TRAIL), promyelocytic leukemia gene (PML), and the deathassociated proteins (DAPs), exert their tumor suppressing functions through
inducing apoptosis in tumor cells [Chawla-Sarkar, et al., 2003]. Interestingly, the
involvements of different ISGs in IFN-induced apoptosis depend on cell types.
For example, TRAIL and XIAP associated factor 1(XAF1) are believed to
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Figure 1.1.3 Mechanism of IFN-induced apoptosis [Zimmermann, 2001]
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contribute to IFN-induced apoptosis in melanoma cells, whereas an induction of
regulators of IFN-induced death (RIDs) is necessary in IFN-induced ovarian
carcinoma cell apoptosis. The survival benefit may invoke a cancer cell to
selectively inhibit one or more of the apoptotic ISGs, or acquire defects in IFNsignal transduction components.

1.1.4 Clinical application of IFNs in cancer treatment
The applications of IFNs in the treatment of cancer have been studied
extensively. To a certain extent, success has been achieved in the treatment of
several malignant hematological diseases and solid tumors by IFNs [Friedman,
2008]. Treatment with IFN-, the first IFN used in the treatment of cancer, results
in significant clinical responses and prolongs survival in patients with hairy cell
leukemia, chronic myelogenous leukemia, renal cell carcinoma, ovarian cancer,
hepatocellular carcinoma, and melanoma [Walter, et al., 1998; Wadler and
Schwartz, 1997; Borden and Parkinson, 1998; Baker, et al., 2002; Borden, et al.,
2002, Borden, et al., 2007 and Hastie, et al., 2008]. Furthermore, clinical trials
have revealed that IFN-
tumors including renal cell carcinoma, Kaposi’s sarcoma, and melanoma. Preclinical studies have shown that IFNs are able to inhibit the growth of prostate
cancer cells. For example, IFN-β increases the expression of the androgen
receptor, improving adhesion potential of androgen-insensitive prostate cancer
cells [Angelucci, 2007]. Forced expression of human IFN-β in human prostate
cancer cells can significantly inhibit the prostatic growth which has been
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correlated with down regulation of angiogenic molecules [Lee, 2006].
Adenovirus-mediated delivery of the IFN-γ gene can inhibit the growth of prostate
cancer cells in vitro and xenografts in vivo [Zhao, et al., 2007]. IFNs have also
been used in clinical trials for prostate cancer patients [Van Haelst-Pisani, et al.
1992; Bulbul, et al. 1986]. However, the role of IFNs in the treatment of prostate
cancer is under-studied, particularly in clinical applications. The limited
application is due to high toxicity accompanied by limited beneficial effect
[Kuratsukuri, et al., 2000]. To solve these problems, IFNs have been used in
combination with other cytotoxic agents for the treatment of prostate cancer in
recent years. For example, IFN- is combined with paclitaxel or 13-cis-retinoic
acid in a phase I clinical trial to treat prostate cancer [Thalasila, et al., 2003]; a
phase II study indicates that IFN-γ as an adjuvant enhances antitumor effects in
131

I-labeled high affinity CC49 monoclonal antibody therapy in patients with

metastatic

prostate

cancer

[Meredith,

et

al.,

1999];

the

combination

chemotherapy of 5-fluorouracil and a low dose of IFN- in patients with HRPC
proves feasible with acceptable toxicity [Shinohara, et al., 1998]. Thus, a
combination of IFN with other cytotoxic agents may be a novel approach for
prostate cancer therapy.

1.1.5 DsRNA and cell apoptosis
The synthetic dsRNA, Polyinosinic:polycytidylic acid ( Poly I:C), is a toll-like
receptor 3 (TLR 3) ligand and a potent inducer of type I IFN. Poly I:C is active
against a number of transplanted tumors, such as melanoma and leukemia [Bart
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and Kopf, 1969; Zeleznick and Bhuyan, 1969]. It can also inhibit the growth of a
variety of human tumor cells in culture, for example colon carcinoma cells and
bladder carcinoma cells [Lin, et al., 1982; Hubbel, et al., 1984]. Poly I: C induces
cell apoptosis through multiple pathways such as TLR3, NF-kappaB, interferon
regulatory factors 3 (IRF3), and the IFN stimulated pathway [Chin, et al., 2010;
Huang, et al., 2006]. Although the therapeutic efficacy and toxicity of dsRNA in
the treatment of cancer patients have been evaluated in the past years, its
striking side-effects have greatly blocked its clinical applications because the
therapeutic responses are observed only at high doses [Friboulet, et al., 2010].
Furthermore, several laboratories have reported that if dsRNA is delivered by
cationic liposome to cancer cells, it can inhibit the growth of many cancer cells
even at a low concentration, suggesting a possible clinical application of dsRNA
[Okamoto, et al. 1998]. It has been observed that 25µg/mL poly I:C can inhibit
LNcap cell (prostate cancer cell) proliferation through the IFN-independent
pathway involving protein kinase C activation; however, 25ug/mL poly I:C only
has slight inhibition effect on the PC3 cell proliferation [Paone, et al., 2008].
Furthermore, it has been reported that human IFN and dsRNA can synergistically
inhibit the growth of some human cancer cells, but studies about the mechanism
are largely lacking [Chapekar and Glazer, 1985; Chapekar and Glazer, 1986].
Also, there are no reported studies on checking the effect of IFNs and dsRNA on
prostate cancer cell apoptosis.
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1.1.6 Our hypothesis
The effect of IFNs on prostate cancer has been studied for decades, but the
limited application of IFNs on the treatment of prostate cancer is due to the
cytotoxicity and lack of efficacy in prostate cancer patients. To solve these
problems, IFNs have recently been used in combination with other cytotoxic
agents for the treatment of prostate cancer. On the other hand, the antitumor
function of the adjuvant molecule poly I:C has been studied extensively; however,
the significantly inhibiting effect of poly I:C on human malignant cells has been
performed with a very high concentration of 100µg/m. Recently, the combination
of low dose of poly I:C with other factors such as the IAP (inhibitor of apoptotic
protein) inhibitor RMT 5265 can produce a synergistic effect on apoptosis
induction and/or inhibition of clonogenic growth [Friboulet, et al., 2010]. Here, we
hypothesis that a low dose of IFNs combined with a low dose of dsRNA may
augment the inhibiting effect on the growth of prostate cancer cells.
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Project II: studies on the biological roles of TMCO1

1.2.1 Human chromosome 1 and its related diseases
Chromosome 1 is the largest of the human chromosomes, spanning about
260 million base pairs and containing 8% of the human genome [Gregory, et al.,
2006]. There are about 3,000 genes on chromosome 1 and due to this great
number of genes, there are also a large number of diseases associated with
chromosome 1. Over 350 human diseases have been linked to the disruption in
the sequence of chromosome 1 including cancers, neurological, developmental
disorders, distinctive facial features, birth defects, cardiovascular disease, and
other medical problems [Ohya, et al., 2006; Povey and Parrington, 1986]. A few
examples include: Parkinson’s disease, familial adenomatous polyposis,
Alzheimer’s disease, porphyria cutanea tarda, Chediak–Higashi syndrome,
Diamond–Blackfan

syndrome,

factor

V

Leiden

thrombophilia,

hereditary

antithrombin III deficiency, Gaucher disease, type 2 hemochromatosis, etc.
[Caramazza, et al., 2010]. Changes to chromosome 1 may include a missing
segment of the short (p) or long arm (q) of the chromosome in each cell (partial
monosomy 1p or 1q), an extra segment of the short or long arm of the
chromosome,

or

a

circular

structure

called

ring

chromosome

1

[http://ghr.nlm.nih.gov/chromosome=1]. For instance, the nonrandom duplication
of the long arm material of chromosome 1, which tends to occur at a relatively
late stage of cancer, may contribute to the progression of all forms of cancer
[Atkin, 1986]. Impressively, chromosome 1 plays an important role in the
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regulation of the development and growth of humans, which can be seen in
several developmental disorders. One disorder, known as1p36 deletion
syndrome, is a disease characterized by typical craniofacial dysmorphism,
developmental delay, and mental retardation. In individuals with1p36 deletion
syndrome, the genetic deletion on the outermost band of the short arm of
chromosome 1 (1p36 chromosome region) occurs, which includes de novo
terminal

1p36

deletion,

interstitial

deletion,

complex

chromosome

rearrangements, 1p36 deletion with a 1p36 duplication, or a derivative
chromosome 1 [Battaglia, et al., 2008]. The clinical features of GLUT1 deficiency
syndrome are mental and developmental delay, hypoglycorrhachia. This
syndrome is caused by various de novo mutations in the facilitated human
glucose transporter 1 gene (1p34.2) [Aktas, et al., 2010]. Chromosome 1q
syndrome is another developmental disorder related to Chromosome 1. The
interstitial deletion of chromosome 1q ( q23-q31) causes pre- and postnatal
growth retardation, severe psychomotor retardation, microbrachycephaly and
some other clinical syndromes [Schwemmle, et al., 2006].

1.2.2 Introduction of the human TMCO1 gene
The human TMCO1 gene is located on chromosome 1q22-q25. TMCO1 is a plasma
membrane-associated protein and belongs to the DUF841 superfamily of several
eukaryotic proteins with unknown functions based on the predicted amino acid sequence
[Zhang, et al., 2010]. TMCO1 is also known as HP10122, PCIA3, PNAS-136, RP11466F5.7 or TMCC4. An earlier study proved that HP10122, an alias for TMCO1, is
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Figure 1.2.1 Ideograms of chromosome 1 (http://ghr.nlm.nih.gov
/chromosome=1)
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located in the endoplasmic reticulum and Golgi apparatus in COS7 cells
( Monkey kidney cell line) by fusing TMCO1 with a green fluorescent protein tag
[Iwamuro, et al., 1999], whereas another recent study showed the porcine
TMCO1 localizing in mitochondrion [Zhang, et al., 2010]. A full-length cDNA
clone HP10122, isolated from human HT-1080 cDNA library, contains a 5’untranslated region of 138bp, an open reading frame of 567bp, and a 3’untranslated region of 481bp [Iwamuro, et al., 1999]. The TMCO1 gene consists
of seven coding exons, and the 564-bp coding region encodes a predicted
protein of 188 amino acids. Figure 1.2.2 shows the schematic structure of
TMCO1 protein [Xin, et al., 2010]. One coiled-coil domain (amino acids 32-89)
and two transmembrane segments (amino acids 10-31 for TM1 and amino acids
90-109 for TM2) were predicted by SMART sequence analysis. Reversible
phosphorylations of serine, threonine, and tyrosine residues are critical steps in
the signal transduction pathways. Previous studies indicate that three
phosphorylation sites (phosphoserines) involved in the signaling networks across
the cell cycle are identified [Olsen, et al., 2006; Nousiainen, et al., 2006; Wang,
et al., 2008; Daub, et al., 2008; Dephoure, et al., 2008; Yachie, et al., 2009].
There are two known isoforms of the human TMCO1 protein which are produced
by alternative splicing.

The expression of TMCO1 transcript is universal in

different tissues; the EST profile of the NCBI database (UniGene Hs.31498)
shows that the TMCO1 transcript was found to be expressed in 42 of 45 adult
tissues examined. Furthermore, mRNA expression of TMCO1 was displayed at
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Figure 1.2.2 Schematic protein structure of TMCO1 [Xin, et al., 2010] One
coiled-coil domain (amino acids 32-89) and two transmembrane segments
(amino acids 10-31 for TM1 and amino acids 90-109 for TM2) were predicted by
SMART sequence analysis. The red stars indicate three verified phosphoserine
residues.
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all developmental stages, including the embryoid body, blastocyst, fetus, neonate,
infant,

juvenile,

and

adult

(http://www.ncbi.nlm.nih.gov/UniGene/ESTProfileViewer.cgi?uglist=Hs.31498).
The HP10122 mRNA was detected by Northern blot analysis as a single band of
1.5kb in various human tissues with different expression levels: highly expressed
in the thymus, prostate, testis and small intestine and scarce in kidney, placenta,
lung, and brain [Iwamuro, et al., 1999]; while in swine, the quantitative PCR
results indicated that the expression of TMCO1 mRNA was higher in the liver,
heart and kidney, significant in doris, logngissimus, backfat, brain, lymph, lung,
large intestine, small intestine and lower in stomach and spleen [Zhang, et al.,
2010]. From the amino acid sequence comparison, it has been known the entire
sequence is highly conserved with 100% homology among eight mammalian
TMCO1 proteins in GenBank [Xin, et al., 2010]; analysis by a SOSUI software
predicts the secondary structure of the TMCO1 protein as a membrane protein
with a transmembrane helix [Zhang, et al., 2010].

1.2.3 TMCO1 defect syndrome
A unique autosomal recessive condition characterized by distinctive
craniofacial dysmorphism, skeletal anomalies, and mental retardation was
described in Old Order Amish of Northeast Ohio. This condition was called
TMCO1 defect syndrome [Xin, et al., 2010]. The typical craniofacial dysmorphism
includes highly arched bushy eyebrows, long eyelashes, brachycephaly,
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synophrys, low-set ears, microdontism of primary teeth, and generalized gingival
hyperplasia; whereas, skeletal anomalies are represented by sprengel deformity
of the scapula, rib abnormities, pes planus, fusion of the spine and pectus
excavatum (Figure 1.2.3). Depressed deep tendon reflexes, unstable gait, and
intention tremor were found in some older patients through neurological
examination.
Through genome-wide single nucleoid polymorphysim (SNP) homozygosity
mapping in affected individuals from a consanguineous pedigree (Figure 1.2.4), a
single large, shared block of homozygous SNPs was identified on chromosome
1q23.3-q24.1, and 23 genes were revealed from the examination of the minimal
shared region. From gene sequencing, homozygous 2-base pair deletion
(c.139_140delAG) within exon 2 of the TMCO1 gene was identified as the
pathogenic change in patients with TMCO1 defect syndrome. It is predicted that
this homozygous frame shift mutation can result in premature truncation of
translation at amino acid position 47.

1.2.4 Biological function of TMCO1
The biological process and function of the TMCO1 gene are still unknown,
and there are few papers available to indicate the biological function of TMCO1.
TMCO1 may be involved in the lipid metabolism, since TMCO1 is downregulated in liver and adipose tissues in response to a 3-day fast [Lkhagvadori, et
al., 2009]. The relationship between TMCO1 and cancers can be found in several
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Figure 1.2.3 Clinical features of TMCO1 defect syndrome [Xin, et al., 2010].
(A-G) Facial characteristics of this syndrome; (H) Brain Magnetic resonance
imaging (MRI) of a patient with TDS indicating prominence of cerebrospinal fluid
space around the frontal lobes with extension into the anterior interhemisheric
fissure; (I) Chest x-ray film of an affected individual showing multiple rib
anomalies.
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Figure 1.2.4 Partial pedigree chart of the family with TMCO1 defect
syndrome [ Xin, et al., 2010]. ■, affected males; □, unaffected males; ●, affected
females; ○, unaffected females; ══, consanguinity.
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studies: meta-analysis of microarray data showed that TMCO1 is upregulated in
breast cancer [Kondrakhin, et al., 2008]; TMCO1 may be a potential
pharmacogenomic predictor in phase II clinical trials of trastuzumab for breast
cancer [Pusztai, et al., 2007]; and in bladder cancer, the previous study indicates
that lipolysis stimulated lipoprotein receptor (LSR) can be upregulated by P53,
which may impair bladder cancer cells from gaining invasive properties.
Affymetrix GeneChips experiment shows that siRNA knockdown of LSR leads to
the down regulation of TMCO1 expression [Herbsleb, et al., 2008]. BCL6 is a
BTB/POZ domain transcription repressor that is required for normal germinal
center development and is expressed by the majority of normal GC B cells and a
subset of diffuse large B cell lymphomas [Polo, et al., 2007]. The BCL6 targeting
proteins are enriched in modulators of transcription, chromatin structure, protein
ubiquitylation, cell cycle, and DNA damage responses. As one of BCL6 targeting
genes, TMCO1’s biological activities may be found among some of these events.
Furthermore, TMCO1 is found to be associated with the onset of diabetes and
renal function in a type II diabetes mouse model. In this study, the TMCO1
transcript ratios in liver, brain, islets, EDL, soleus muscle, and adipose between
diabetes-susceptible DBA/2J mice and diabetes-resistant C57BL/6J mice were
calculated [Dokmanovic-Chouinard, et al., 2008]. TMCO1 may be involved in the
regulation of renal water excretion through altered Aquaporin-2 (a molecular
water channel). Altered Aquaporin-2 protein, which is abundant in the renal
collecting duct, is the main factor responsible for water balance abnormalities
associated with different clinical states.
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TMCO1 is one of Aquaporin-2’s

transcriptional regulators and is expressed only in the medullary thick ascending
limb cells and renal proximal tubule cells in native rats, but not in the renal
collecting duct [Yu, et al., 2009]. Most recently, other possible functions of
TMCO1 may be outlined by Musashi 1 study. Musashi1 is a highly conserved
RNA-binding protein with pivotal functions in stem cell maintenance, nervous
system development, and tumorigenesis. TMCO1 is one of the Musashi1associated mRNAs, which implicates that the TMCO1’s biological function is
related to at least one of Musashi 1’s functions: 1) cell cycle, cell proliferation, cell
differentiation, and apoptosis; 2) protein modification (including ubiquitination and
ubiquitin cycle); and 3) tumor formation [De Sousa Abreu, et al., 2009]. In
summary, more work needs to be done to dig out the systematic functions of
TMCO1.
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CHAPTER II
HUMAN PROSTATE CANCER CELL APOPTOSIS INDUCED BY
INTERFERON-γ AND DOUBLE-STRANDED RNA

2.1 Abstract
Interferons (IFNs) are a family of pleiotropic cytokines responsible for inducing
innate and adaptive immunities against a wide-range of viruses and other
microbial pathogens. IFNs also exert antitumor activities due to their antiproliferative, immunomodulatory, and proapoptotic functions. In recent years,
studies have revealed that a combination of IFNs with cytotoxic compounds,
such as paclitaxel and thalidomide, augments the cytotoxicity for prostate cancer
cells in an additive manner. Here we report that pretreatment of PC3 cells, a
human prostate adenocarcinoma cell line, with IFNs sensitized these cells to
dsRNAs-induced apoptosis. The enhancement effect of IFN treatment was
dependent on IFN subtypes, particularly IFN-γ. In comparison with IFN-α or ,
IFN-γ treatment remarkably augmented dsRNA-induced apoptosis in PC3 cells,
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and by using mutant cell lines, we demonstrated that IFN-signaling is necessary
for these effects. The silencing of dsRNA-dependent protein kinase R (PKR) and
RNase L by siRNA did not have any significant impact on this event, suggesting
that neither RNase L nor PKR is involved in this event. Further investigation of
the apoptotic pathway revealed that Bak, a pro-apoptotic member of the Bcl-2
family, was up-regulated by IFN-γ and dsRNA. Our findings may lead to the
design of novel therapeutic strategies for prostate cancer.

2.2 Introduction
Although prostate specific antigen (PSA) screening and digital rectal
examination have been used widely for the early detection of prostate cancer,
which bring a dramatic decrease in the mortality rate from prostate cancer, there
are still a certain amount of patients who undergo disease progression after
receiving primary treatment [Strief, et al., 2007; Pienta, 2009; Bantis and Vasiliou,
2009; Bickers and Aukim-Hastie, 2009; Damber and Aus, 2008]. The choices of
treatment for patients who are diagnosed with metastatic diseases are limited.
The first line treatment for men with metastatic advanced prostate cancer is
androgen ablation therapy using either luteinizing hormone releasing hormone
(LRHR) agonists or surgical castration. Despite the early efficacy of hormone
ablation therapy, the success of it is short-lived; almost all cases progress to an
androgen insensitive state called hormone-refractory prostate cancer (HRPC)
[Priolo, et al., 2009]. Currently there is no cure for the disease at this stage.
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The molecular biological characteristics of prostate cancer have been studied
intensively, and many small-molecule inhibitors and recombinant humanized
monoclonal antibodies have been tested in the preclinical setting. Although
promising results have been achieved, many of them have not yielded clearly
favorable results. Cytotoxic chemotherapy was thought to be the best choice in
this situation, and recent studies have shown that docetaxel, a semi-synthetic
analog of paclitaxel, can achieve a remarkable improvement on the survival of
HRPC patients by inducing mitotic catastrophe and caspase-2 and -3-dependent
apoptosis followed by freezing the entire microtubule network [Mediavilla-Varela,
et al., 2009; Fabbri, et al., 2008]. Docetaxel has thus become the standard
treatment for metastatic HRPC; however, lack of a response and development of
resistance to docetaxel in a considerable number of patients limit its applications
in prostate cancer therapy. Although the actions of other antitumor drugs in
hormone-resistant prostate cancer were tested and examined, the efficacy of
current therapy for hormone-refractory prostate cancer is still unsatisfactory
[Fabbri, et al., 2010]. Therefore, development and discovery of new drugs
capable of prolonging survival have become an urgent clinical need.
IFNs are a family of cytokines expressed in eukaryotic cells as an early
response to various stimuli, such as viruses, bacteria, parasites, double-stranded
RNA, and immune inducers [Stark, et al., 1998]. The use of IFNs in the treatment
of cancer has been studied extensively, and during the recent decades the
quantity of survivals and quality of lives for many cancer patients have been
improved dramatically by IFN treatments [Damasio, et al., 2000]. By reviewing
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literature, a potent synthetic dsRNA IFN inducer, poly I:C, was found to be active
against a number of transplanted tumors which can also inhibit the growth of a
variety of human tumor cells in culture [Bart and Kopf, 1969; Zeleznick and
Bhuyan, 1969; Lin, et al., 1982; Hubbel, et al., 1984]. However, there are few
studies concerning the exact mechanism of how these effects are accomplished,
and the effect of IFNs and dsRNA on prostate cancer cell apoptosis has not been
reported. In the present study, we found that the pretreatment of PC3 cells with
IFN-γ sensitized these cells to small amounts of dsRNA-induced apoptosis.
Further, we demonstrated that IFN-signaling is necessary for these effects and
Bak, a pro-apoptotic member of the Bcl-2 family, was up-regulated by IFNγ/dsRNA. Our findings may be beneficial in the design of novel therapeutic
strategies for prostate cancer.

2.3 Materials and methods

Reagents and antibodies
Poly I:C was from Sigma (St. Louis, MO). IFN α, IFN-β and IFN-γ were from R
& D Systems (Minneapolis, MN). Antibodies to Bax, Bak, Bim, Caspase 3 and
PKR were from Santa Cruz Biotechnology, Inc (Santa Cruz, CA). Anti--actin
antibody was purchased from Chemicon (Temecula, CA).
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Cell culture and treatments
PC3 cells, a human prostate cancer cell line (ATCC, Manassas, VA), were
grown in RPMI-1640 medium (Media Lab of the Central Cell Service, Cleveland
Clinic, Cleveland, OH) supplemented with streptomycin (100µg/mL), penicillin
(100unites/mL) and 10% cosmic calf serum (Hyclone, Logan, UT) in a humidified
atmosphere of 5% CO2 at 37 oC. Cells were grown to 90% confluence and
incubated with 1000units/mL of IFN α, IFN-β or IFN-γ respectively for 18 h
followed by transfection with or without 2µg/mL of poly I:C using lipofectomine
(Invitrogen, Carlsbad, CA). Culture medium was added at 1 h after transfection.
The effects of IFNs and dsRNA on the cell growth were also examined on DU145
cells, another prostate cancer cell line (ATCC, Manassas, VA).

Cell viability assay
Three days after treatments, the medium color of the cultured cells was
recorded and the trypan blue dye exclusion assay was used to count viable cells.
This assay is based on the principle that live cells possess intact cell membranes
that exclude certain dyes, such as trypan blue, eosin, or propidium, whereas
dead cells do not. In this test, a cell suspension is simply mixed with dye and
then visually examined to determine whether cells take up or exclude dye. Cells
were visualized under Olympus CKX31 at 100X magnification.
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Annexin V assay
To determine whether the inhibiting effect of IFN-γ/dsRNA on PC3 cells’
growth resulted from apoptosis, an Annexin V assay was performed.
Phosphatidylserine (PS) is a type of phospholipid (Figure 2.3.1). Under normal
conditions, PS is situated in the inner leaflet of the cell membrane, but at the
early stage of apoptosis, PS is translocated to the outer leaflet of the cell
membrane due to the loss of membrane asymmetry. Anenexin-V conjugated with
flurochromes has very high affinity to PS, so the amount of cells undergoing early
stage apoptosis can be quantified by measuring the florescence signals using
flow cytometry. At the same time, the cells are stained with propidium iodine (PI)
which is another kind of flurochrome. In the late stage of apoptosis the cell
membrane is disintegrated, allowing PI to enter the cells and bind to the DNA.
Thus, the cells undergoing later stage apoptosis can be evaluated by PI signals.
Shown on the right part of Figure 2.3.1 is a typical Annexin-v assay result. The xaxis represents the number of cells undergoing early stage apoptosis and the yaxis represents the amount of cells undergoing later stages of apoptosis. The
signals in the right upper area indicate the total amount of cells that undergo
apoptosis.
In this study, Annexin V assay was performed using an Annexin VFITC/propidium iodine apoptosis detection kit (BD Biosciences, San Jose, CA).
Briefly, PC3 cells treated as described previously were collected and centrifuged
at 2,000Xg for 5 min at 4oC. Then cells were washed with ice cold PBS and
resuspended in 1X binding buffer provided by the manufacturer. FITC Annexin-V
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Phosphatidylserine

(PS) is a type of phospholipid. At the early stage of apoptosis, PS is retranslocated to the outer leaflet from the inner leaflet of the cell membrane and
bound to Anenexin-V, which is conjugated with flurochromes. Apoptotic cells are
sorting by the florescence signals using flow cytometry. Propidium iodine (PI),
which is another type of flurochrome, is able to penetrate the disintegrated cell
membrane of apoptotic cells to bind to the DNA. Thus, the cells undergoing later
stage apoptosis can be evaluated by PI staining.
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(5 µL) and propidium iodide (5 µL) were added to cell suspension containing
1X105 cells for each assay. After incubation for 15 min in the dark at room
temperature, 400 µL of 1X binding buffer was added to the cell suspension and
cells were analyzed by two-color cytometry using a FACScanTM (Becton
Dickinson, Franklin Lake, NJ).

Determination of DNA fragmentation
DNA fragmentation represents a characteristic hallmark of apoptosis and the
DNA fragmentation assay is another typical method used for evaluating cell
apoptosis. During apoptosis, endonuclease is activated and subsequently
degrades the DNA molecules in the region between the nucleosomes so that the
consequent DNA fragments are essentially multiples of 200-base-pair lengths.
In this study, DNA in the IFNs/dsRNA treated cells was isolated using an
apoptotic DNA ladder kit (Roche, South San Francisco, CA). Briefly, 200 μL of
cell suspensions in PBS was mixed with 200 μL binding buffer (Roche, South
San Francisco, CA). After incubation for 10 min at room temperature, 100 μL of
isopropanol (Mallinckrodt Baker, Phillipsburg, NJ) was added to the samples,
followed by vortexing. DNA was then purified using glass fibers. DNA samples
with ethidium bromide staining were separated on 2% agarose gel and visualized
under UV light.
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TUNEL assay
To further confirm whether IFN-γ combined with dsRNA induces PC3 cell
apoptosis, we performed a terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) assay. Shown on Figure 2.3.2 is the working principle of a
TUNEL assay. Basically terminal deoxynucleotidyl transferase (TdT) is used to
transfer deoxyuridine triphosphates (dUTP) conjugated with a fluorochrome to
these strand breaks of cleaved DNA and the total amount of strand breaks in the
cleaved DNA is evaluated with flurochrome, such as FITC, by flow cytometry.
The TUNEL assay was performed using an APO-BRDU kit (BD Biosciences,
San Jose, CA). Briefly, IFNs/dsRNA treated PC3 cells were scraped, collected
and fixed in 1% paraformaldehyde for 45 min followed by washing with PBS
twice. Then cells were stored in 70% ethanol at -20oC until staining and analysis.
DNA fragmentation was examined by incorporating Brdu and staining with a
FITC-labeled anti-BrdU mAb. The total DNA breaks were determined with FITC
and the labeled cells were sorted by flow cytometry in a FACS.

Caspase activity assay
Caspase 3 belongs to a family of cysteine proteases (caspases) that cleave
proteins at aspartate residues [Strasser, et al., 2000]. Caspase 3 is the
executioner of cell death in the cell apoptotic pathway and it is worthwhile to
examine the activity of caspase 3 to evaluate cell apoptosis. The activity of
caspase 3 in the cells treated with IFN-γ and /or dsRNA was examined using
CaspACETM Assay system (Promega, Madison, WI) as instructed by
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transferase (TdT) is used to transfer deoxyuridine triphosphates (dUTP)
conjugated with a fluorochrome to these strand breaks of cleaved DNA and the
total amount of strand breaks in the cleaved DNA is evaluated with flurochrome,
such as FITC, by flow cytometry.
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manufacturer. This assay is based on caspase cleavage of chromophore pnitroaniline (pNA) substrate linked with the tetrapeptide DEVD. Free pNA
produces a yellow color that is monitored by spectrophotometer at 405 nm. In
brief, cells were treated as described above and cytosolic extracts were prepared
by cell lysis buffer provided by the manufacturer. After centrifugation at 15,000Xg
for 20 min at 4 oC, cell extract containing 50 µg of proteins were transferred into a
96-well plate to mix with the CaspACETM assay reagent. After incubation for 4 h
at 37 oC, caspase activity was determined by absorbance at 405 nm using a
LD400 AD/LD analysis spectrometer (Beckman Coulter, Brea, CA).

Western blot analysis
The expressions of several proteins in the apoptotic pathway were examined
by western blot analysis. PC3 cells were harvested after being treated with IFNs
and/or dsRNA. Cytoplasmic extracts were prepared by suspension of cell pellets
in NP-40 lysis buffer [Zhou, et al., 2005]. After centrifugation in a microcentrifuge
at 40C for 10 min, the supernatant was removed and stored at –800C. Cellular
extracts were fractionated on SDS-10% polyacrylamide gels and transferred to
polyvinylidene difluoride membranes (Millipore, Billerica, MA). The membranes
were blocked with 5% non-fat milk in PBS containing 0.02% sodium azide and
0.2% (v/v) Tween 20 and incubated with different primary antibodies overnight at
4oC. The membranes were then washed with PBS containing 0.2% (v/v) Tween
20 and incubated with corresponding secondary antibodies conjugated with HRP
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(Cell Signaling Technology, Boston, MA) for 1 h at room temperature. After
washing, these proteins were detected by a chemiluminescence method,
according to the manufacturer’s specification (Amersham, Piscataway, NJ).

Inhibition of the expression of dsRNA-dependent protein kinase R (PKR) in
PC3 cells by small interference RNA (siRNA)
PC3 cells were transfected with a heterogeneous mixture of 21-23 bp PKR
siRNA (New England Biolab, Ipswich, MA) using the transpass R2 transfection
reagent (New England Biolab, Ipswich, MA) according to the manufacturer's
instructions. Briefly, PC3 cells were grown to 50% confluence. PKR siRNA was
incubated with the transfection reagent in serum-free medium for 20 min at room
temperature. Subsequently, the mixture was evenly dispersed on the cells that
had been washed with serum-free medium once. The final concentration of
siRNAs was 12.5 nM.

After being incubated for 3 h, the complete culture

medium was added to the cells. At 30 h after transfection the cells were treated
with IFNs and dsRNA as described previously. The apoptotic effects of these
treatments on the PKR siRNA transfected PC3 cells were analyzed. Meanwhile,
part of the transfected cells were lysed and western blotting analysis was
performed to determine the expression of PKR in PC3 cells.
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Inhibition of the expression of RNase L in PC3 cells by small interference
RNA (siRNA)
A pool of 3 target-specific 20-25 nt RNase L siRNA designed to knock down
the RNase L gene expression was purchased from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA). PC3 cells were transfected with RNase L siRNA to knock
down the expression of RNase L in PC3 cells using the Lipofectamine 2000
transfection reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s
instruction. Briefly, before transfection, PC3 cells were cultured with antibioticfree medium in 60-mm plates overnight and the cells were ready for transfection
when the cell confluence was around 50%. Ten μL of lipofectamine 2000 was
added to 300 μL of serum free medium. After being incubated for 5 min at room
temperature, another 300 μL serum free medium containing 8.3 μL of RNase L
siRNAs was added to this mixture and incubated for 20 min at room temperature.
Then the mixture was dispersed evenly to cells. The final concentration of RNAse
L siRNA was 26 nM. After 4 h, the medium was replaced with complete culture
medium. At 30 h after transfection, part of the RNAse L siRNA transfected cells
were collected and pelleted for western blot assay to examine whether the
expression of RNase L was knocked down and part of the RNAse L siRNA
transfected cells were treated with IFNs and/or dsRNA as indicated previously.
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2.4 Results

IFN-γ and dsRNA synergistically decrease PC3 cells viability
The cytotoxicity of IFNs has limited its clinical application in the treatment of
cancers; thus the combinations of IFNs with other cytotoxic agents have recently
been the new direction for the use of IFNs in cancer treatments. To determine
the direct effect of IFNs and dsRNA on prostate cancer cells, we treated the PC3
cells with IFNs and poly I:C. Three days after treatment, the medium color of the
cells treated with IFN-γ/dsRNA remained pink while medium color of cells treated
in other ways became yellow (Figure 2.4.1). When cells grow well, the medium
color will change from pink to yellow due to a change in pH as a result of cell
waste products; therefore the pink medium in the IFN-γ/dsRNA treated well
indicated that most cells in this well were dead. Cell viability was analyzed by
trypan blue exclusion assay; all treated cells exhibited a decrease in their viability,
but IFN-γ/dsRNA showed a notably stronger ability to suppress PC3 cell growth
when compared with other types of treatment as shown in Figure 2.4.2. Similar
results were visualized under Olympus CKX31 at 100X magnification (Figure
2.4.3). To rule out the bias caused by prostate cancer cell lines, we conducted
the same experiment on DU145 cells, another prostate carcinoma cell line, and
similar results were obtained. Most of the IFN-γ/dsRNA treated DU145 cells died,
while the cells treated in other ways showed normal morphology (Figure 2.4.4).
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Figure 2.4.1 IFN-γ and dsRNA synergistically decrease PC3 cell viability.
PC3 cells were treated with 1,000 units/mL of IFN ,  or  overnight, and then
transfected with or without 2 µg/mL of dsRNA using the lipofectomine reagent.
The picture was taken on day 3 of the post treatment.

50

Cell numbers 1 x 10^5/ml

400
300
200
100
0

1

2

3

4

5

6

7

8

Figure 2.4.2 Growth of PC3 cells are inhibited significantly by the IFNγ/dsRNA treatment. PC3 cells were treated with 1,000 units/mL of IFN ,  or 
overnight, and then transfected with or without 2 µg/mL of dsRNA using
lipofectomine. After 48 h, the cells’ viability was analyzed by a trypan blue
exclusion assay. 1, Control; 2, dsRNA alone; 3, IFN-α; 4, IFN-; 5, IFN-γ; 6, IFNα/dsRNA; 7, IFN-/dsRNA; 8. IFN-γ/dsRNA
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Figure 2.4.3 Morphology of PC3 cells treated with IFN-γ/dsRNA PC3 cells
were treated with 1,000 units/mL of IFN ,  or  overnight, and then transfected
with or without 2 µg/mL of dsRNA using lipofectomine. After 3 days, cells were
visualized under Olympus CKX31 at 100 x magnification.
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Figure 2.4.4 IFN-γ and dsRNA synergistically inhibit the growth of DU145
cells. DU145 cells were treated with 1,000 units/mL of IFN ,  or  overnight,
and then transfected with or without 2 µg/mL of dsRNA using lipofectomine. After
3 days, cells were visualized under Olympus CKX31 at 100 x magnification.
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IFN-γ/dsRNA induce apoptosis in PC3 cells
To determine whether the decreased PC3 cell viability was actually a result of
IFN-γ/dsRNA-induced apoptosis, the translocation of membrane phospholipids
phosphatidylserine (PS) from the inner to the outer leaflet of the plasma
membrane was examined as an early event of cell apoptosis. Annexin V is a 3536kD Ca2+ dependent, phospholipids-binding protein that has a high affinity for
PS. Therefore, FITC-conjugated Annexin V is commonly used to identify
apoptotic cells at an early stage. The Annexin-FITC staining showed that 21.4%
of PC3 cells were positively labeled with Annexin V after being treated with IFNγ/dsRNA, while 4.45% of cells were labled when cells were treated with dsRNA
only and in IFN-α/dsRNA- and IFN-β/dsRNA-treated wells there were 6.58% and
6.31% of cells labeled respectively. These results indicated that the combination
of IFN-γ and dsRNA is a potent inducer of PC3 cell apoptosis (Figure 2.4.5). To
further confirm that IFN-γ combined with dsRNA can induce PC3 cell apoptosis,
we performed a TUNEL assay. In TUNEL assay, terminal deoxynucleotidyl
transferase (TdT) is used to transfer Br-dUTP to the strand breaks of cleaved
DNA. The total amount of strand breaks in the cleaved DNA was evaluated with
Anti-Brdu antibody conjugated with FITC. As shown on Figure 2.4.6, the
combination of IFN-γ and dsRNA induced 4 times more cells undergoing
apoptosis than IFN-γ- or dsRNA-treatment did. We next evaluated apoptosis by
DNA fragmentation assay. During apoptosis, endonuclease is activated and cuts
the DNA molecules in the region between the nucleosomes and then the
consequent DNA fragments are essentially multiples of 200-base-pair lengths. In
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this experiment, only the IFNγ/dsRNA treated lane showed DNA fragments,
suggesting that only IFNγ/dsRNA induced PC3 cell apoptosis (Figure 2.4.7).

IFN-γ/dsRNA activate caspase 3
To further characterize the IFNγ/dsRNA induced apoptosis in prostate cancer
cells, we determined the activity of caspase 3 in IFN-γ and/or dsRNA treated
PC3 cells. The activity of caspase 3 in the cells treated with IFN-γ and/or dsRNA
was examined by CaspACETM Assay system (Promega, Madison, WI). IFNγ/dsRNA induced the activity of caspase 3 in PC3 cells by 2.8-fold while IFN- γ or
dsRNA increased the caspase 3 activity by 1.1- and 1.7-fold respectively (see
figure 2.4.8).

IFN-γ/dsRNA enhance the expression of Bak
Apparently, IFN-γ combined with dsRNA was able to effectively induce PC3
cell apoptosis; the next question is what the molecular mechanism is by which
IFN-γ /dsRNA activate the apoptotic pathway. In mammalian cells, there are two
major apoptotic pathways, termed “extrinsic” and “intrinsic” [Elmore, 2007]. The
extrinsic pathway, also termed as the Death Receptor Pathway, is activated by
the binding of a “death” ligand to its receptor. Subsequently the adapter proteins
FADD and caspase 8 are recruited to the intracellular portion of the receptor,
resulting in the activation of caspase 8 and caspase 3--the executioner of cell
apoptosis. Cellular stress initiates the intrinsic apoptotic pathway, also termed as
the Mitochondrial Pathway, and involves the upregulation of BH3-only proteins
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such as Bim, PUMA, and Bad. These proteins inhibit the activity of the antiapoptotic Bcl-2 proteins, resulting in Bax dimerization and translocation to the
mitochondria, subsequently triggering the release of cytochrome C. Then
Cytochrome C combined with APAF-1 and caspase 9 forms apoptosome and
further promotes caspase 3 cleavage and activation, leading to apoptosis (see
Figure 2.4.9).

To test how IFN-γ and dsRNA affect the apoptotic signaling

pathways, several members of this pathway were examined using western blot
analysis. Bak, a pro-apoptotic member of the Bcl-2 family, was upregulated by
IFN-γ/dsRNA (see Figure 2.4.10). The full length of caspase 3 was significantly
decreased in IFN-γ/dsRNA treated cells, suggesting that caspase 3 was cleaved
and activated to trigger cell apoptosis. However, there was no significant
difference in the expression of Bax, Bim and caspase 8 among different
treatments.

JAK/SATA pathway is involved in IFN-γ/dsRNA induced PC3 cell apoptosis
It is believed that IFNs execute most of their functions through IFN’s Jak-stat
signaling pathway [Borden, et al., 2007]. To examine the role of Jak-stat pathway
in the IFN-γ/dsRNA-induced prostate cancer cell apoptosis, we determined two
mutant cell lines: U3A and LNcap cells. The U3A cell is a stat1 null human
fibrosarcoma cell line and the 2FTGH cell is its parental cell line, while the LNcap
cell is a prostate cancer cell line with Jak1 deficiency. In these experiments, U3A
and LNcap cells were treated as previously described and the cell viability was
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Figure 2.4.5 Determination of PC3 cell apoptosis by Annexin-V analysis
PC3 cells were pretreated with 1,000 units/mL of IFN ,  or  overnight and then
treated with 2µg/mL of dsRNA and subjected to Aneexin-V assay by flow
cytometry after 20 h incubation.
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Figure 2.4.6 Determination of PC3 cell apoptosis by TUNEL assay PC3 cells
were pretreated with 1,000 units/mL of IFN ,  or  overnight and treated with 2
µg/mL dsRNA. After 20 h, the cells were scraped, collected and fixed in 1%
paraformaldehyde for 45 min, followed by washing with PBS twice. Then cells
were stored in 70% ethanol at -20oC until staining and analysis. DNA
fragmentation was examined by incorporating Brdu and staining with a FITClabeled anti-BrdU mAb. The total DNA breaks were determined with FITC and
the labeled cells were sorted by flow cytometry.
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Figure 2.4.7 IFN-γ and dsRNA induce DNA fragmentation in PC3 cells DNA
in the IFNs/dsRNA treated cells was isolated using an apoptotic DNA ladder kit
(Roche, South San Francisco, CA), separated by agarose gel, stained with
ethidium bromide and visualized under UV light.
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Figure 2.4.8 Caspase 3 activity assay The activity of caspase 3 in PC3 cells
treated with IFN-γ and /or dsRNA for 10 h was examined using CaspACE TM
Assay system. Briefly, the treated cells were lysed and the cell extract containing
50 µg of proteins was transferred into a 96-well plate to mix with the CaspACETM
assay reagent. After incubation for 4 h at 37 oC, caspase activity was determined
by absorbance at 405 nm using a LD400 AD/LD analysis spectrometer.
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Figure 2.4.9 A scheme of major apoptotic pathways in mammalian cells
(www.healthcare.uiowa.edu/research/sfrbm/papers/.../Tome-Apoptosis.ppt)
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Figure 2.4.10 Effect of IFN-γ and dsRNA on the expression of apoptotic
proteins PC3 cells were harvested after being treated with IFNs and/or dsRNA
for 20 h. Cellular extracts were fractionated on 10% SDS-PAGE and transferred
to PVDF membrane. The membranes were blocked with 5% no fat milk in PBS
containing 0.02% sodium azide and 0.2% (v/v) Tween 20 and incubated with
different primary antibodies overnight at 4oC. The membranes were then washed
with PBS containing 0.2% (v/v) Tween 20 and incubated with corresponding
secondary antibodies conjugated with HRP for 1 h at room temperature. After
washing, these proteins were detected by a chemiluminescence method.
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examined by trypan blue exclusion assay. As expected, both U3A and LNcap
cells were not responded to the IFN-γ/dsRNA treatment (Figure 2.4.11, Figure
2.4.12, and Figure 2.4.13), suggesting that the Jak-stat signaling pathway is
necessary for the IFN-γ/dsRNA-induced prostate cancer cell apoptosis.

PKR is not involved in the IFN-γ/dsRNA induced PC3 cell apoptosis
As mentioned previously, IFNs, in most cases, induce apoptosis through
stimulating the expression of certain IFN-stimulated genes (ISGs). Here we
checked the role of several ISGs in the IFN- γ/dsRNA-induced apoptosis. PKR is
a proapoptotic protein. As shown in Figure 2.4.14 [Samuel, 2001], after being
induced by IFNs, PKR is activated by dsRNA, commonly from viral infection
(ssRNA forms some dsRNA segments in its secondary structure). The activated
PKR phosphorylates the eukaryotic initiation factor 2α and subsequently inhibits
mRNA translation. As a result, viral replication and cell proliferation are inhibited.
Previous studies have demonstrated that PKR can mediate cell apoptosis in
various cell types [Jagus, et al., 1999]. To test whether PKR is involved in IFNγ/dsRNA-induced PC3 cell apoptosis, the expression of PKR in PC3 cells was
knocked down by PKR siRNA, and then the cells were treated with IFNs/dsRNA
as previously described. The results showed that IFN-γ combined with dsRNA
had similar effects on the PKR knockdown PC3 cells as on normal PC3 cells
(Figure 2.4.15). The expressing level of PKR in PC3 cells is very low and PKR
does not respond to IFN-γ induction either. To prove that PKR siRNA can knock
down the expression of PKR effectively, the siRNA trasfected cells were treated
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with 1000 unites/mL of IFN- and then western blot analysis was conducted to
examine PKR protein expression. As shown in Figure 2.4.16, PKR siRNA
effectively knocked down the expression of PKR in the cells. Thus, these results
ruled out the involvement of PKR in IFN-γ/dsRNA-induced apoptosis in PC3 cells.

RNase L is not involved in the IFN-γ/dsRNA induced PC3 cell apoptosis
RNase L is another dsRNA related ISG. It is one of the key enzymes for the
IFN’s function against cell proliferation and viral infection. In this system, IFNs
induce the expression of oligoadenylate synthetase (OAS), whose activity is
regulated by dsRNA. OAS catalyzes the synthesis of oligoadenylates of the
general structure pp(A2’p)n, commonly abbreviated as 2-5 A. As a latent
endoribonuclease, RNase L is activated by the binding of 2-5A and leads to the
degradation of viral and cellular RNA. As a result, viral replication is inhibited and
cells undergo apoptosis (Figure 2.4.17) [Samuel, 2001]. To test whether RNase L
contributes to IFN-γ/dsRNA induced PC3 cell apoptosis, the expression of
RNase L in PC3 cells was knocked down by RNase L siRNA (Figure 2.4.18) and
then the cells were treated as previously described. Our results showed that
although the expression of RNase L was knocked down by RNase L siRNA, PC3
cells were still sensitive to the treatment of IFN-γ/dsRNA (Figure 2.4.19). The
expression of RNase L in PC3 cells treated with different IFNs and/or dsRNA
was also examined by a western blot assay (Figure 2.4.20). These results
showed that IFN-γ/dsRNA treatment did not induce a significant difference in the
expression of RNase L.

64

35

Cell Number 1X10^4/ml

30
25
20
15
10
5
0

Control

dsRNA

IFN-γ

IFN-γ/dsRNA

Figure 2.4.11 Effect of IFN-γ/dsRNA on the viability of LNcap cells LNcap
cells were treated with IFN-γ and/or dsRNA for 72 h and the viability of the
treated cells was analyzed by a trypan blue exclusion assay.
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Figure 2.4.12 Effect of IFN-γ/dsRNA on the viability of U3A cells U3A cells
were treated with IFNs and/or dsRNA. The viability of the treated cells was
analyzed by a trypan blue exclusion assay. 1, Control; 2, dsRNA alone; 3, IFN-α;
4, IFN-; 5, IFN-γ; 6, IFN-α/dsRNA; 7, IFN-/dsRNA; 8. IFN-γ/dsRNA
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Figure 2.4.13 Effect of IFN-γ/dsRNA on the viability of 2FTGH cells. 2FTGH
cells were treated with IFNs and/or dsRNA. The viability of the treated cells was
analyzed by a trypan blue exclusion assay. 1, Control; 2, dsRNA alone; 3, IFN-α;
4, IFN-; 5, IFN-γ; 6, IFN-α/dsRNA; 7, IFN-/dsRNA; 8, IFN-γ/dsRNA
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Figure 2.4.14 Role of PKR in IFNs’ functions [Samuel, 2001]
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Figure 2.4.15 Role of PKR in IFNs/dsRNA-induced PC3 cell apoptosis PC3
cells were transfected with PKR siRNA. At 30 h after transfection, the cells were
treated with IFNs and/or dsRNA. The apoptotic cells were analyzed by a trypan
blue assay. 1, Control; 2, dsRNA alone; 3, IFN-α; 4, IFN-; 5, IFN-γ; 6, IFNα/dsRNA; 7, IFN-/dsRNA; 8, IFN-γ/dsRNA
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Figure 2.4.16 Knockdown of PKR by siRNA in PC3 cells PC3 cells were
transfected with PKR siRNA and then were treated with 1000 unites/mL of IFN-.
The expression level of PKR in the cells was analyzed by a western blot analysis.
1, Control; 2, IFN-α; 3, PKR siRNA; 4, PKR siRNA+IFN-α
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Figure 2.4.17 The 2-5 A system [Samuel, 2001]
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Figure 2.4.18 Knockdown of RNase L by siRNA in PC3 cells PC3 cells were
transfected with RNase L siRNA using the Lipofectamine 2000 reagent. After 30
h incubation, the cells were collected, lysed and a western blot analysis was
performed to evaluate the protein expression of RNase L.
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Figure 2.4.19 Role of RNase L in IFN-γ/dsRNA induced PC3 cell apoptosis
The RNase L knockdown cells were treated with IFN-γ and/or dsRNA and the
viability of the treated cells was analyzed by a trypan blue exclusion assay.
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Figure 2.4.20 Expression of RNase L in IFNs/dsRNA treated PC3 cells A
western blot analysis was conducted to evaluate the protein expression of RNase
L in PC3 cells treated with IFNs and/or dsRNA.
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INF-γ has no effect on the expression of death associate protein 3 (DAP3)
and 5 (DAP5)
Death associated proteins (DAPs) are uniquely induced by IFN-γ, and the role
of DAPs in mediating IFN-γ induced apoptosis in certain cell types has been well
established in recent years [Kissil,et al., 1995; Hirota, et al., 2004]. To determine
whether DAPs are responsible for IFN-γ/dsRNA-induced PC3 cell apoptosis,
DAP3 and DAP5 were examined by Western blot analysis. The results showed
that there was no difference in the expression of DAP3 and DAP5 between the
control and IFN-γ treated PC3 cells (Figure 2.4.21). This suggests that DAP3 and
DAP5 were not responsible for this event.
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Figure 2.4.21 Expression of DAPs in IFN-γ treated PC3 cells PC3 cells were
treated with 1000 unit/mL of IFN- and the expression of death associated
proteins (DAPs) was analyzed by a western blot assay.
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2.5 Discussion
In this study, we examined the effect of dsRNA and IFNs on the apoptosis of
PC3 cells and discovered that pretreatment of human PC3 prostate cancer cells
with IFNs, especially IFN-γ, significantly enhances the vulnerability of these cells
to dsRNA-induced apoptosis. Similar results were obtained on DU145 cells which
are another type of prostate cancer cell line, while other types of cancer cells
displayed a dramatic difference in response to the stimulation with the subtypes
of IFN.
RNase L and PKR are two IFN-inducible proteins which are very important in
many IFN regulated events. Previous studies showed that increased expression
of 2-5A syntheses was observed in both HeLa cells and mouse L-cells treated
with IFN-β and dsRNA [Nilsen et al., 1981; Goswami and Sharma, 1984].
Furthermore, INF-γ is able to induce the expression of 2-5A synthetase in human
colon carcinoma cell line BE, but there is no synergistic effect observed in the
combination of IFN-γ and dsRNA [Chapekar and Glazer, 1986]. These results
are consistent with our finding that RNase L-deficient PC3 cells are still sensitive
to the treatment of IFN-γ and dsRNA. In addition, there was no overt difference
in the RNase L expression in the cells treated with or without the dsRNA/IFN-γ.
All of these suggest that RNase L may not be involved IFN-γ/dsRNA-induced
apoptosis in PC3 cells. Magnusson et al. [2006] reported that arthritis triggered
by dsRNA is not dependent on PKR. In the present study, after the expression of
PKR was knocked down by siRNA, the PC3 cells were still sensitive to the
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treatment of IFN-γ/dsRNA, suggesting again that PKR does not participate in the
event.
The JAK/STAT pathway has been well established during the studies on the
IFNs’ function. It has been observed that Stat1 is required for IFN-inducible
responsiveness to the extracellular dsRNA [Elco and Sen, 2007]. Arthritis
triggered by dsRNA is associated with the ability to produce type I IFN and is
critically dependent on type I IFN receptor signaling [Magusson et al., 2006]. U3A
cells, which lack STAT1, were not sensitive to IFN-γ/dsRNA. However, IFNγ/dsRNA are able to synergistically induce apoptosis in 2ftgh, the parental cells
of U3A, implicating that the JAK/STAT pathway is necessary for this event.
Furthermore, LNcap cells, which are deficient in Jak1, were resistant to the IFNγ/dsRNA treatment. Taken together, these data indicate the JAK/STAT pathway
is indispensable for the apoptosis induced by IFN-γ/dsRNA in PC3 cells.
Either dsRNA or IFN- is able to induce a broad range of gene expressions
[Potten and Wilson, 2004]. In the global profiling of dsRNA and IFN-γ-induced
genes in rat pancreatic beta cells, one of the BCL-2 family members, Bax, is
highly inducible [Rasschaert, et al., 2003]. Noxa is another protein induced by
the cells exposed to dsRNA, interferon, and virus [Sun and Leaman, 2005]. To
determine whether any of the Bcl-2 family members is involved in PC3 cell
apoptosis induced by IFN-γ/dsRNA, we examined the expression of several Bcl-2
family proteins and found that Bak was upregulated by IFN-γ/dsRNA, implying
that apoptosis in PC3 cells induced by IFN-γ/dsRNA depends on the participation
of mitochondria.
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CHAPTER III
STUDIES ON THE BIOLOGICAL ROLES OF TRANSMEMBRANE AND COILEDCOIL DOMAINS 1

3.1 Abstract
Transmembrane and coiled-coil domains 1 (TMCO1) is a membraneassociated protein and belongs to the DUF841 superfamily of several eukaryotic
proteins with unknown functions. The human TMCO1 gene is located on
chromosome 1q22-q25. A homozygous frame shift mutation in the TMCO1 gene,
c.139_140delAG, has been identified in patients with TMCO1 defect syndrome
(TDS). TDS is characterized by distinctive craniofacial dysmorphism, skeletal
anomalies, and mental retardation. To further investigate the biological functions
of TMCO1, we first attempted to generate an antibody against TMCO1 protein. In
this study, human TMCO1 was expressed in both bacteria and mammalian cells.
The recombinant TMCO1 expressed in bacteria was purified in preparation for a
workable antibody. Subcellular localization using the immune-fluorescent staining
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technique revealed that TMCO1 may be mainly expressed in the mitochondria of
cells. Interestingly, the lymphocytes isolated from the peripheral blood of the
patients with TDS grew significantly faster than those from healthy individuals,
suggesting that TMCO1 may be involved in the regulation of cell proliferation. In
addition, we have generated a TMCO1 knockdown cell line, which can be used
for further the study of the molecular basis underlying TDS.

3.2 Introduction
TMCO1 is a plasma membrane-associated protein located in the long arm of
the 1st chromosome. Recently, it was found that the homozygous mutation in
TMCO1 caused a syndrome with craniofacial dysmorphism, skeletal anomalies
and mental retardation, named TMCO1 defect syndrome (TDS) [Xin, et al., 2010].
TDS is an autosomal recessive condition in Old Order Amish of Northeastern
Ohio, and a homozygous 2-base pair deletion within exon 2 of the TMCO1 gene
was identified. Though the function of this gene is still unclear, distribution
analyses revealed that TMCO1 is universally expressed in all human tissues and
is highly conserved among multiple species. The ubiquitous expression pattern
in human adult and fetal tissues and the high sequence conservation may
suggest that TMCO1 plays important biological roles. Structural analysis
indicates that the TMCO1 gene consists of one coiled-coil domain and two
transmembrane domains, and there are 3 phosphoserine residues identified,
which may participate in signaling transduction. Currently, the study concerning
the function of TMCO1 is largely lacking, although some reports show that the
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TMCO1 gene is regulated by different events--for instance, fast, cancer, and
diabetes. [Lkhagvadorj, et al., 2009; Kondrakhin, et al. 2008; DokmanovicChouinard et al., 2008; Yu, et al., 2009]. In this study, we subcloned the TMCO1
gene into several mammalian cell expression vectors and an ectopic expression
of the gene in different cell types. By using these cell lines we determined the
localization of TMCO1 and examined the effect of TMCO1 on cell functions. We
also generated an effective antibody against human TMCO1. Based on the
results obtained from lymphocyte cells derived from TDS patients and TMCO1
knockdown cell lines, TMCO1 may play an important role in cell proliferation.

3.3 Materials and methods

Materials and reagents
Human TMCO1 cDNA was purchased from ATCC (Manassas, VA). pET-21d
vector was from Novagen (Brookfield, WI). pIREShyg vector was purchased from
Clontech (Brookfield, WI ). Choice-Taq™ DNA Polymerase was from Denville
Scientific INC. (Metuchen, NJ). All digestion enzymes and the T4 DNA ligase kit
were obtained from New England Biolab (Ipswich, MA). The QIAEXii gel
extraction and QIAprep Spin Miniprep kits were purchase from Qiagen (Valencia,
CA). SOC medium and ultrapure agarose were from Invitrogen (Carlsbad, CA).
XL10-gold ultrocompetent cell was from Stratagen (Kirkland, WA).
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Subcloning of TMCO1 to pET-21d
To express TMCO1 in E. coli, TMCO1 cDNA was subcloned to pET-21d
vector with a His-tag (Figure 3.3.1).

The TMCO1 cDNA was amplified by

polymerase chain reaction (PCR) from pOTB7 vector in a reaction mixture (50
μL) containing 10 mM Tris-HCl (pH 8.3), 10 mM KCl, 1.5 mM MgCl2, 8mM
(NH4)2SO4, 0.05% NP-40, 200 mM each deoxynucleoside triphosphate, 1.0 U of
Taq polymerase, and 0.5 μg of a pair of primers. The first denature step was
done at 94°C for 3 min. The PCR amplification was carried out for 30 cycles
consisting of template denaturation (1 min at 94°C), primer annealing (45 sec at
55°C), and polymerization (1 min at 72°C). The final extension step was 1 cycle
of 72oC for 8 min. The forward primer used was 5’GGT GCG ACC ATG GGC
ACT ATG TT3’ and the reverse primer was 5’AGA ACT CCT CGA GAG AGA
ACT TCC3’. Both PCR products and pET-21d vector were digested with
restriction enzymes XhoI and NcoI. The digestion reaction mixture (50 μL)
included 5 μL of PCR product or pET-21d vector DNA, 5 μL of buffer 2 and 3 μL
of XhoI and ddH2O. The mixture was incubated at 370C for 1 h followed by
adding additional 3 μL of NCOI and 2 μL of NaCl (0.1 M) then incubated for
another 1 h. Both the PCR product digestion mixture and pET-21d vector
digested mixture were separated by 1% agarose gel and undergone gel
purification using the QIAEXii gel extraction kit. A T4 DNA ligase kit was used to
ligate the DNAs. The ligation buffer contained 5 μL of pET-21d digestion mixture,
4 μL of PCR product digestion mixture, 2 μL of 10X T4 buffer, 1 μL of T4 ligase,
and distilled-deionized water (ddH2O) to 20 μL in total. The ligation reaction was
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done at room temperature for 2 h, followed by transformation. Briefly, the mixture
of 10 μL of ligation solution and 50 μL of XL10-gold ultracompetent cell (good for
big size cloning) was left on ice for 30 min, 40 0C water bath for 90 sec, and ice
for 2 min. Then 300 μL of SOC medium was added to the mixture and the tube
was shaken at 370C for 1 h. Three hundred μL of the mixture was applied to a LB
agarose plate with ampcillin (100 μg/mL) and incubated overnight at 37 0C. In the
next morning, 12 single clones were picked up and grown in LB medium.
TMCO1/pET-21d plasmid DNA was extracted using the QIAprep Spin Miniprep
kit and trasformed to E. coli BL21 (DE3) competent cells (Sigma, St. Louis, MO)
for protein expression. The authenticity of the clones was confirmed by DNA
sequencing.

Subcloning of TMCO1 to pIREShyg
In order to express the TMCO1 gene in mammalian cells, TMCO1 cDNA was
cloned to a pIREShyg vector. TMCO1 was amplified by PCR from the plasmid
pOTB7 as previously described. The primers used for this PCR were 5’ CTA
CGG ATC CCG TTT TCG CTT C3’ (forward) and 5’ GGC TCT GGA TCC AAA
ACA GTT G3 (reverse). Both PCR product and pIREShyg vector (Figure 3.3.2)
were digested with BamH1. After digestion, the DNAs were treated with alkaline
phosphatase calf intestine (CIP) at 37oC for 30 min, followed by gel purification.
The purified DNAs were ligated, and then transformed as described above.
Purified TMCO1/ pIREShyg plasmid DNA was kept for the transfection.
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Other subclonings
Several other constructs were generated. (1) TMCO1-pFLAG-CMV-2 (Figure
3.3.3): primers used were 5’CGG CCG CGA ATT CGA GCA CTA TGT TC3’
(forward) and 5’GGC TAC CTA TGG CTC TTG CT3’ (reverse). EcoR1 and XbaI
were used to digest the DNAs. (2) TMCO1-pCMV-Myc (Figure 3.3.4): the primers
were the same as used for cloning TMCO1 to pFLAG-CMV-2, but restriction
enzymes were EcoR1 and XhoI. (3) TMCO1-pCMV-HA (Figure 3.3.5): the
primers were 5’AGG TGC GAA TTC AGA CTA TGT TCG C3’ (forward) and
5’GAA AGA GGC TCG AGT AGT AAG GCT A3’ (reverse). EcoR1 and XhoI were
used to digest the DNAs.

Immunofluorescence staining
Human U87 cells were human glioblastoma-astrocytoma cells (ATCC,
Manassas, VA). Cells were grown in RPMI-1640 medium (Media Lab of the
Central Cell Service, Cleveland Clinic, Cleveland, OH) supplemented with
streptomycin (100 µg/mL), penicillin (100 unites/mL) and 10% cosmic calf serum
(Hyclone, Logan, UT) in a humidified atmosphere of 5% CO2 at 37 oC. U87Cells
were seeded on BD FalconTM CultureSlides (BD Biosciences, Bedford, MA) and
transfected with the pFlag-CMV-2 vector or pFlag-CMV-2/TMCO1 plasmid DNA
using lipofectomine 2000 reagents (Invitrogen, Carlsbad, CA). After 30 h,
transfected cells were incubated with growth medium containing 0.5 µM
MitoTracker Red CMXRos (Invitrogen, Carlsbad, CA) for 15 min at 37 oC and
immunofluorescence was performed following standard protocols. In brief, after
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Figure 3.3.1 pET-21d vector map (Novagen, Brookfield, WI)
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Figure 3.3.2 pEREShyg vector information (Clontech, Brookfield, WI)
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Figure 3.3.3 pFLAG-CMV-2 vector information (Eastman Kodak Company,
New Haven, CT)
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Figure 3.3.4 pCMV-Myc vector information (BD Biosciences, Palo Alto, CA)
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Figure 3.3.5 pCMV-HA vector map and MCS (BD Biosciences, Palo Alto, CA)
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being rinsed with 1XPBS (Media Lab of the Central Cell Service, Cleveland
Clinic, Cleveland, OH), the cells were fixed with 3% formaldehyde (Sigma, St.
Louis, MO) for 15 min at room temperature, followed by 3 times of washing with
PBS. The cells were then permeabilized with ice-cold methanol (PharmcoAAPER, Shelbyville, KY) for 10 min at -200C and blocked with block buffer (2.5
mL of 10XPBS, 1.25 mL of normal goat serum, 75 μL of Triton X-100 and dH2O
to 25 mL) for 60 min at room temperature, followed by incubation in primary
antibody, a mouse monoclonal anti-Flag M5 antibody (Sigma-Aldrich, St. Louis,
MO) overnight at 40C. Then the cells were rinsed with 1XPBS for 3 times and
incubated with the secondary antibody: Dylight

TM

488 conjugated Anti-mouse

IgG (Cell signaling, Boston, MA), for 1.5 h at room temperature in dark. After 5
times of washing with high salt PBS (0.4 M NaCl, 1XPBS), the walls of culture
slides were removed, and the nuclei were counterstained with DAPI (Invitrogen,
Carlsbad, CA). Then the slides were mounted with Prolong Gold Antifade
Reagent (Invitrogen, Carlsbad, CA) and the edges of cover slips were sealed
with nail polish. The slides were examined using a Delta Vision RT microscope.

TMCO1 protein expression in E. coli BL21 cells
E.coli BL21 cells bearing TMCO1/pET-21d construct were grown in LB
medium supplemented with ampicillin (100 μg/mL) to an O.D. value of 0.5 at 600
nm and the expression of TMCO1 was induced by adding isopropyl
thiogalactoside (IPTG) to a final concentration of 1 mM. After being shaken at
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30oC for 6 h, bacterial cells were harvested by centrifugation (1750 Xg at 40C for
30 min). The cell pellets were frozen at -800C.

Purification of TMCO1
The cell pellets were thawed and resuspended in lysis buffer (50 mM
phosphate buffer with 800 mM NaCl, pH 8.0, 0.1% Triton X-100) on ice, followed
by sonication and centrifugation to sediment cell debris. The supernatant was
diluted with 6 M guanidine HCl in 1:1 volume ratio to a final concentration of 25
mM phosphate, 400 mM NaCl and 3 M guanidine HCl (pH 8.0). Then the diluted
supernatant was mixed with a nickel-chelating histidine-binding resin (Qiagen,
Valencia, CA) for 1 h and loaded into an empty column. After washed with PBS
buffer containing 20 mM immidazole and 3 M guanidine HCl, the TMCO1 protein
was eluted with PBS buffer containing 100 mM immidazole and 3 M guanidine
HCl (pH 8.0). Fractions containing TMCO1 were pooled and dialyzed against 4 L
Tris-buffered saline (1 mM EDTA, 1 mM benzamidine and pH 7.4) at 4 0C. The
dialyzed sample was stored at -800C until use.

Production of polyclonal anti-TMCO1 antibody
The amino acid sequence of TMCO1 was “MSTMFADTLLIVFISVCTALLAEG
ITWVLVYRTDKYKRLKAEVEKQSKKLEKKKETITESAGRQQKKKIERQEEKLKN
NNRDLSMVRMKSMFAIGFCFTALMGMFNSIFDGRVVAKLPFTPLSYIQGLSHRN
LLGDDTTDCSFIFLYILCTMSIRQNIQKILGLAPSRAATKQAGGFLGPPPPSGKFS
,” which was submitted to GenSript Company (Piscataway, NJ) together with Hek
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293 cell lysate as a positive control for pepetide polyclonal anti-TMCO1 antibody
production. The antigen peptide designed and synthesized by GeneScript
company was “CKIERQEEKLKNNNR.” To gain an effective immunization effect,
the peptide was conjugated with a big molecule Keyhole limpet hemocyanin
(KLH). Then the conjugated peptide antigen was used to immunize 6 rabbits.
Affinity purification was used to purify the TMCO1 antibody from the serum of
immunized rabbits.

RNA isolation and RT-PCR
The lymphocytes from normal, carrier (one copy of TMCO1 gene was
mutated), and affected (both copies of TMCO1 gene were mutated) individuals
were pelleted in 15 mL centrifuge tubes and washed with PBS twice. The total
RNA was isolated using Trizol (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. Briefly, 3 mL of Trizol reagent was added to the tube.
After a brief vortex, 0.8 mL of chloroform was added followed by vigorous vortex
for 1 min. Samples were centrifuged at 10,000 x g for 30 min at 4 oC and the
colorless upper aqueous phase was moved to a new 15 mL centrifuge tube. After
added equal amount of isopropyl alcohol and inverted for several times, the
sample sat at room temperature for 10 min followed by centrifugation at 10,000 x
g for 20 min at 4oC. Then the RNA precipitate formed a gel-like pellet on the side
and bottom of the tube. The supernatant was discarded and 1mL of 80% ethanol
(pre-cooled at –20oC) was used to suspend RNA. The RNA suspension was
transferred to a new 1.5 mL microcentrifuge tube and centrifuged at 7,000 x g for
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5 min at 4oC. Then the alcohol was removed as much as possible and the RNA
was dissolved in 100 µL of diethyl pyrocarbonate (DEPC) (Sigma-Aldrich, St.
Louis, MO)-treated RNase-free H2O by passing several times through a pipette
tip.
One-step RT-PCR was performed using a SuperScriptTM One-Step RT-PCR
with Platinum Taq Kit (Invitrogen, Carlsbad, CA) according to the manufacturer's
instructions. First strand cDNA synthesis and pre-denaturation steps were done
at 45oC for 30 min and 94oC for 2 min and were followed immediately by PCR
amplification. PCR amplification conditions were as follows: 35 cycles of
denaturation at 94oC for 1 min, annealing at 55oC for 45 sec, and extension at
72oC for 1 min 30 sec. Finally, 1 cycle of final extension was set at 72 oC for 8 min.

Western blot analysis
Lymphocytes were harvested from normal, carrier, or affected individuals.
Cytoplasmic extracts were prepared by suspension of cell pellets in NP-40 lysis
buffer. After centrifugation in a microcentrifuge at 4 0C for 10 min, the supernatant
was removed. Cellular extracts were fractionated on SDS-12% polyacrylamide
gels and transferred to polyvinylidene difluoride membranes (Millipore, Billerica,
MA). The membranes were blocked with 5% non-fat milk in PBS containing

0.02% sodium azide and 0.2% (v/v) Tween 20 and incubated with TMCO1
antibody (Genescript, NJ) overnight at 4oC. The membranes were then washed
with PBS containing 0.2% (v/v) Tween 20 and incubated with anti-rabbit IgG
secondary antibody conjugated with HRP (Cell Signaling Technology, Boston,
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MA) for 1 h at room temperature. After the washing step, these proteins were
detected by a chemiluminescence method, according to the manufacturer’s
specification (Amersham, Piscataway, NJ). The expression of TMCO1 in different
cell lines was examined.

Knockdown of TMCO1’s expression
Oligonucleotides coding for short hairpin RNA (shRNA) specifically against
TMCO1 were cloned into pSilence 4.1-CMV neo (Ambion, Austin, TX). The
following target regions of TMCO1 were chosen: (1) GCCAUAGGUAGCCUUACUA;
(2)

GCAAGUUGGCUGUCUAUGA

and

(3)

CAAGGAGAGAUCUGUUUCA.

Stably transfected clones were established by selection with G418 (Calbiochem,
Brookfield, WI). The TMCO1 expression in each picked clone was examined by
western blot assay.

Growth rate of lymphocytes from patients with TMCO1 defect
To check the effect of TMCO1 on the growth of lymphocytes, 6.27X10^5 of
lymphocytes from normal, carried, or affected individuals were seeded to each
flask respectively. Cells were counted using trypan blue dye exclusion assay
after 6 days and the medium color of each flask was recorded.
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3.4 Results

TMCO1 was subcloned to the pET-21d and pIREShyg vectors
In order to explore the function of TMCO1, we attempted to prepare an antiTMCO1 antibody by using a purified recombinant TMCO1 protein. TMCO1 cDNA
was subcloned into the pET-21d vector, which was fused with a His tag, using
XhoI and NCOI.

Several clones were identified as the right clones and the

constructs were further confirmed by DNA sequencing (Figure 3.4.1 and Figure
3.4.2). In addition, TMCO1 was inserted into pIREShyg using Bam H1 and the
constructs were confirmed by DNA sequencing as well (see Figure 3.4.3).

Purification of the recombinant TMCO1 protein
The purification of recombinant TMCO1 was achieved by using metal
chelation affinity chromatography. As shown in Figure 3.4.4, after induction, the
expressed TMCO1 protein in the cell lysate was passed through an affinity
column packed with Ni2+ saturated beads and the bound recombinant TMCO1
protein was eluted with 100 mM immidazole after the column was washed with
20 mM immidazole. The insolubility of a recombinant protein expressed in
bacteria is a common problem. To increase the yield, 6 mM guanidine
hydrochloride (GnCl) was added to the cell lysate to promote the solubility of the
recombinant TMCO1 protein during the purification process. After purification,
GnCl was removed by dialysis. The purified protein was analyzed by SDS-PAGE
(Figure 3.4.5). However, although the purity of the purified recombinant TMCO1
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PCR products

PCR products digested
w/ restriction enzyme

Vectors digested
w/ restriction enzyme

Figure 3.4.1 Digestion of PCR products and vectors TMCO1 cDNA was
amplified by PCR and both PCR products and vectors were digested with
corresponding restriction enzymes.
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1 2 3 4 5 6 7 8 9 10 11 12
5.4kb

560bp

Figure 3.4.2 TMCO1/pET-21d clone selection After subcloing, 12 clones were
picked up and cultured in LB medium. Plasmid DNA was purified from each clone
and digested by XhoI and NCOI.
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1 2 3 4 5 6 7 8 9 10 11 12

4.3kb
2.2kb

Figure 3.4.3 TMCO1/pIREShyg clone selection After subcloing, 12 clones were
picked up and cultured in LB medium. Plasmid DNA was purified from each clone
and digested by XbaI.
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20 mM
imidazole

100 mM
imidazole

250 mM
imidazole

75KDa
50KDa
37KDa

TMCO1

20KDa

Figure

3.4.4

Purification

of

TMCO1

protein

by

nickel

affinity

chromatography E.coli BL21 cells bearing TMCO1/pET21-d construct were
grown in LB medium supplemented with ampicillin (100 μg/mL) to an OD value of
0.5 at 600 nm and the expression of TMCO1 as induced by adding IPTG to a
final concentration of 1mM. After being shaken at 30oC for 6 h, bacteria cells
were pelleted, lysed, and mixed with nickel charged beads. The impurities were
washed away by 20 mM imidazole and most TMCO1 protein was eluted by 100
mM imidazole. The collection from each step was separated by SDS-PAGE and
stained by Coomassie brilliant blue.
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75KD
50KD
37KD

TMCO1

20KD

Figure 3.4.5 Purified TMCO1 protein
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protein was very good, it was difficult to prepare a sufficient amount of protein to
immunize an animal. Thus, we lately made an anti-TMCO1 antibody by using
synthesized peptides.

Localization of TMCO1
To determine the subcellular localization of TMCO1, U87 cells were
transfected with either TMCO1- pFLAG-CMV-2 or TMCO1- pCMV-HA. After 48 h,
the cells were labeled with antibodies against FLAG or HA, respectively, and
then stained with Dylight

TM

488 conjugated Anti-mouse IgG. As shown in Figure

3.4.6, TMCO1 was localized in mitochondria of U87 cells. However, the result
needs to be further confirmed.

TMCO1 mRNA, but not the protein, is expressed in the lymphocytes of
patients with TMCO1 defect syndrome
To investigate the expression of TMCO1 at the transcriptional level in the
lymphocytes of patients with TDS, the total RNA was extracted from the cells
isolated from normal, carrier and affected individuals, and the mRNA expression
levels of TMCO1 were examined by RT-PCR (Figure 3.4.7). GAPDH was
examined as a control. Apparently, there was no significant difference at the
level of TMCO1 mRNA between the normal individuals and patients with TDS. To
determine the expression of TMCO1 at its protein level, cell lysate obtained from
the cells of normal and carrier individuals as well as patients with TDS, were
subjected to a western blot analysis. As expected, there was not a full length of
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Figure 3.4.6 Subcellular localization of pFlag-CMV-2 conjugated TMCO1 in U87 cells U87 cells were
transfected with the pFlag-CMV-2 vector or pFlag-CMV-2/TMCO1 using the lipofectomine 2000 reagent. After 30
h, the cells were incubated with growth medium containing the mitochondrial marker for 15 min at 37oC and
immunofluorescence was performed using an anti-Flag primary antibodies and a Dylight TM 488 conjugated
second antibody. DNA was counterstained with DAPI. The cells were analyzed using a Delta Vision RT
microscope.

TMCO1
GAPDH

Figure 3.4.7 TMCO1 mRNA expression in human lymphocytes The total RNA
of the lymphocytes from normal, carrier, and affected individuals was isolated

using the Trizol reagent and the mRNA expression was evaluated by One-step RTPCR.
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TMCO1
Actin

Figure 3.4.8 TMCO1 protein expression in human lymphocytes Cell extracts
of lymphocytes from normal, carrier and affected individuals were separated by
12% SDS-PAGE. A western blot assay was conducted using an anti-TMCO1
primary antibody.
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TMCO1 protein detected in the cell extract from patients with TDS, which
supports the conclusion drawn previously based on the observation of the
patients’ phenotypes (Figure 3.4.8).

TMCO1 is ubiquitously expressed in all cells examined
In order to examine the differential distributions of TMCO1 in human cells, the
relative protein expression levels of TMCO1 were evaluated by a western blot
analysis in prostate cancer cell lines (PC3 and LNcap), brain cancer cell
line(U87), ovarian cancer cell line (Hey1B), liver cancer cell lines (HEPG2,
HEP3B, A549, H292 and H522), neuroblastoma cell line (N1E115), fibrosarcoma
cell line (HT1080), and embryonic kidney cell line (Hek 293). Although TMCO1 is
ubiquitously expressed in all cells examined, its expression was relatively higher
in PC3 cells, LNcap cells, Hey 1B cells, HEOG2 cells, HEP3B cells and H522
cells (Figure 3.4.9).

TMCO1 is knocked down by TMCO1 shRNA in U87 cells
To investigate the biological role of TMCO1, we knocked down TMCO1 in
U87 cells. The cells were transfected with TMCO1 shRNA pSilence4.1-CMVneo,
and selected in medium containing 400 ug/mL of G418. Four groups of
constructs, one scrambled shRNA and three different TMCO1 shRNAs, were
used to transfect the cells. Twelve clones from each group were examined by
western blot analysis using a polyclonal antibody to human TMCO1. As shown in
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Figure 3.4.10 and Figure 3.4.11, the expression of TMCO1 was significantly
knocked down in the clones: B2, B5, and C7.

TMCO1 may be involved in the regulation of cell proliferation
Since one of the phenotypes in patients with TDS was abnormally growing,
we determined the effect of TMCO1 on cell proliferation. Interestingly, we found
that the lymphocytes from the affected patients grew much faster than the cells
from normal and carried individuals (Figure 3.4.11). The doubling time of the
lymphocytes from the patients was 36 h, whereas the cells from the healthy
individuals needed 48 h to reach the cell numbers. This observation was
confirmed by the medium color in the cell seeded with the same number of
lymphocytes. Overtly, lymphocytes from the patients consumed nutrients much
faster (Figure 3.4.12). Furthermore, TMCO1 knocked down cells such as B2, B5
and C7 also grew 1.5-fold faster than control cells. These results suggest that
TMCO1 may play an important role in cell proliferation.
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TMCO1
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1.
2.
3.
4.
5.
6.

PC3 (prostate cancer)
LNcap (prostate cancer)
U87 (brain cancer)
Hek293 (embryonic kidney )
Hey1B (ovarian cancer)
N1E115 (neuroblastoma)

7. HEPG2(liver cancer)
8. HEP3B(liver cancer)
9. A549 (lung cancer)
10. H292 (lung cancer)
11. H522(lung cancer)
12. HT1080 (sarcoma)

Figure 3.4.9 TMCO1 expression in different cell lines Cell extracts were
obtained from different cell lines as indicated and the expression of TMCO1
protein was determined by a western blot analysis using anti-TMCO1 antibody.

111

A7

A8

B3

C3

A12 A10 B2 B4

A6

A4

B5

B1

B6

B9

C7 C10 D5

D9 D10

B7 B8 C2 C4 C9 D2

D12
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D1
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D7

Figure 3.4.10 TMCO1 knockdown clone selection U87 cells were stably
trasfected with TMCO1 shRNA construct using lipofectomine 2000 and the
clones were selected by 400 µg/mL of G418. The expression of TMCO1 in the
selected clones was determined by a western blot analysis using an anti-TMCO1
antibody. A, mock (control); B, C and D, TMCO1 shRNA
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TMCO1
Actin

Figure 3.4.11 TMCO1 is knocked down by TMCO1 shRNA
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Cell number, 10^6
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10.21875
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2

3.75

4

Normal

6287(Carrier)

0
6300(Affected)

Figure 3.4.12 Effect of TMCO1 on the growth of human lymphocytes
Lymphocytes from normal, carrier, and affected individuals were seeded at
6.27X105 cells in each flask and the cells were counted by a trypan blue dye
exclusion assays after 6 days.
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R-6301A

R-6300A

R-6289

R-6288

R-6287

Normal

Figure 3.4.13 Medium color changes related to the growth of human
lymphocytes Lymphocytes from normal, carrier, and affected individuals were
seeded at 6.27X105 cells in each flask and the medium color in the flasks was
recorded on day 6. Carrier: R-6287, R-6289 and R-6301A; Affected: R-6288 and
R-6300A
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3.5 Discussion
TMCO1 is a transmembrane protein with one coiled coil domain. The coiled
coil is a structural motif in proteins in which 2-7 alpha-helices are coiled together
like the strands of a rope. It has been found that approximately 10% of all protein
sequences have coiled coil motifs which are extremely stable and responsible for
the oligomerization of proteins in a highly specific manner [McFarlane, et al.,
2009]. The functions of coiled coil type proteins are diverse and are involved in
different important biological processes including cytokinesis (Lee, et al., 2008),
gene transcription (Landschulz, et al., 1988) and regulation (Nooren, et al., 1999),
membrane fusion (Deng, et al., 2006), molecular motors (Yun, et al., 2003),
muscle fibres (Strelkov, et al.,2002), apoptotic cleavage site (Lin, et al.,2007),
multidrug resistance (Higgins, et al., 2004), and the potential delivery systems
either in the development of novel vaccines (Schroeder, et al.,2009) or for the
treatment of cancer (Erikssonet, et al., 2009). The universal expression of
TMCO1 in all tissues examined [Xin, et al., 2010; Zhang, et al., 2010; Iwamuro,
et al., 1999] and the highly evolutionary conservation in large animals implicate a
critical role of TMCO1. Our result showed that TMCO1 may be located in the
mitochondria of U87 cells, which is consistent with previous findings that TMCO1
is located in the mitochondria of PK-15 cells (pig kidney cells). As an energy
plant in the body, one of the main mitochondrial functions is to produce cellular
ATP which is essential for eukaryotic cells. There are many nuclear encoded
proteins which are imported into the intermembrane space of mitochondria where
they adopt a coiled coil fold and can perform either oxidoreductase or
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metallochaperon function [Banci, et al., 2009]. These characteristics of TMCO1
may give a hint about its biological function in cells.
TDS is a unique autosomal recessive condition with significant clinical
phenotypes including generalized dimorphism disorders with craniofacial,
skeletal, and CNS features such as brachycephaly and mental retardation. The
molecular mechanism by which TMCO1 defect causes these clinical features is
of great interest. One striking characteristic in several TSD patients is tall stature
[Xin, et al., 2010]. It is possible that TMCO1 controls the elongation of the bones
and dysmorphic proportion [Scotos and Argente, 2008]. Tall stature can be seen
in several other syndromes. For instance, estrogen, as a factor to arrest growth,
is deficient in aromatas deficiency, estrogen receptor deficiency, and
hypogonadism which result in the tall stature. FBN1, TGFBR2, FBN2, and
cystathionine -synthase are essential for inhibiting elongation of the bones and
dysmorphic proportion, the defect of these genes leads to Marfan syndrome I,
Marfan syndrome II, Beads syndrome, and homocystinuria type 1 respectively
[Argente, et al., 2000]. Our results showed that the lymphocytes from patients
with TDS grew significantly faster than that from normal individuals, suggesting
that TMCO1 may be involved in cell proliferation, cell cycle, cell growth, and
tumor suppression. Further investigation needs to be done to elucidate how
TMCO1 contributes to the cell proliferation.
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